Back to top

pharmaceuticals: Archive

Zacks Equity Research

Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment

Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.

RHHBY LLY GSK VIR

Zacks Equity Research

Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug

Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.

PFE MRK NVS BMY

Zacks Equity Research

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.

PFE MRK GSK NVS

Mark Vickery

Stimulus or No? Plus News from GILD, Earnings from INTC & MAT

Gilead (GILD) shares are up 4% in late trading on an announcement that the FDA has granted full approval to its remdesivir treatment.

MAT INTC GILD

Zacks Equity Research

Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.

BIIB REGN GILD VRTX BSTC CRSP

Zacks Equity Research

AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon

Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.

JNJ AZN PFE MRNA

Kinjel Shah

6 Low Price-to-Book Stocks That May Prove to be Solid Bets

When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

BEN TEVA SPB CNC VIAC ATCO

Zacks Equity Research

Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

RHHBY BMY EBS PRTA

Zacks Equity Research

Aclaris (ACRS) Begins Phase II Study on Eczema Candidate

Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.

ACRX ABBV ACRS AMRX

Zacks Equity Research

AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review

AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.

AZN RHHBY MRK VRTX

Zacks Equity Research

Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

AZN MRK GSK SGEN

Zacks Equity Research

Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

PFE MRK MRNA GSK

Mark Vickery

Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell

Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.

VZ CSX ABT CMG TMO TSLA

Zacks Equity Research

Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.

GILD MRK LLY GSK

Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT

The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT

AMT HD AMZN INTC SNY

Zacks Equity Research

AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure

The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.

JNJ AZN LLY VRTX

Zacks Equity Research

AbbVie (ABBV) Files for Rinvoq in Atopic Dermatitis in US & EU

AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Rinvoq ??? atopic dermatitis. The drug is already marketed to treat rheumatoid arthritis.

BIIB NVS AMGN ABBV

Swayta Shah

Bet on These 5 Top-Ranked Stocks With Strong Sales Growth

Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.

MMM PKI SWK VRTX AJG

Zacks Equity Research

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.

PFE MRK GSK BNTX

Zacks Equity Research

Vertex Pharmaceuticals (VRTX) Enters Oversold Territory

Vertex Pharmaceuticals (VRTX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

VRTX

Sheraz Mian

Top Analyst Reports for NVIDIA, salesforce & AstraZeneca

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), salesforce.com (CRM) and AstraZeneca (AZN).

NVDA JPM CVX CRM CHTR AZN

Zacks Equity Research

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

MRK GSK BMY VRTX SGEN

Zacks Equity Research

Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod

Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).

REGN SNY RHHBY ABBV

Sheraz Mian

Top Stock Reports for Amazon, Home Depot & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), The Home Depot (HD) and Sanofi (SNY).

SNY SAP INTC HD AMZN AMT

Zacks Equity Research

Lilly to Acquire Private Biotech for Boosting Pain Portfolio

Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.

PFE LLY VRTX ITCI